

# Sarcoma Kaposi

[View the current Sarcoma Kaposi InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Sarcoma_Kaposi.html)

([http://www.bioportfolio.com/indepth/Sarcoma\\_Kaposi.html](http://www.bioportfolio.com/indepth/Sarcoma_Kaposi.html))



## Recent Publications on Sarcoma Kaposi:

- [Human immunodeficiency virus and liver transplantation: our point of view.](#)  
*INTRODUCTION: Highly active antiretroviral therapy (HAART) has been able...*1st October, 2008  
Liver and Multivisceral Transplant Center, University of Modena and Reggio- Transplant Proc. 2008 Jul-Aug;40(6):1965-71. ([DOI Direct Link](#))
- [Risk factors in the development of Kaposi's sarcoma.](#)  
*INTRODUCTION: Highly active antiretroviral therapy (HAART) has been able...*25th September, 2008  
Cancer Research UK Institute for Cancer Studies, University of Birmingham,- AIDS. 2008 Aug 20;22(13):1629-32. ([DOI Direct Link](#))
- [\[Classic dissemination of Kaposi's sarcoma: report of a case\]](#)  
*An 86-year-old male presented with a disseminated dermatosis characterized...*25th September, 2008  
Servicio de Dermatologia,- Dermatol Online J. 2008 Mar 15;14(3):9.
- [The Influence of a HAART regimen on the expression of HIV-associated Kaposi sarcoma.](#)  
*We report a case of Ewing sarcoma/peripheral primitive neuroectodermal...*20th September, 2008  
- J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):111. ([DOI Direct Link](#))
- [Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.](#)  
*Between 1984 and 2006, 12 959 people with HIV/AIDS (PWH) in the Swiss HIV...*18th September, 2008  
International Agency for Research on Cancer, 150 cours Albert Thomas,- Br J Cancer. 2008 Sep 2;99(5):800-4. Epub 2008 Jul 29. ([DOI Direct Link](#))
- [Kaposi's sarcoma in a patient with AIDS.](#)  
*We report a case of a 40 year old HIV infected male, citizen of Somalia...*16th September, 2008  
Department of Dermatology and Veneorology, Grant Medical College and Sir- J Assoc Physicians India. 2008 Apr;56:262-4.
- [\[Doxil--pegylated liposomal doxorubicin\]](#)  
*Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated...*16th September, 2008  
Dept. of Infectious Diseases, Komagome Metropolitan Hospital.- Gan To Kagaku Ryoho. 2008 Aug;35(8):1439-43.
- [High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides.](#)  
*OBJECTIVE: To investigate the presence of human herpesvirus 8 (HHV-8) in...*13th September, 2008  
Department of Dermatology, Ruhr University Bochum, Gudrunstrasse 56,- Arch Dermatol. 2008 Aug;144(8):1011-6. ([DOI Direct Link](#))
- [Conjunctival Kaposi's sarcoma in HIV-positive heterosexual Nigerian woman--a case report.](#)

*BACKGROUND: Neoplastic conditions are increasingly been encountered in...*5th September, 2008  
Department of Medicine, University of Ilorin Teaching Hospital, Kwara- West Afr J Med. 2008  
Jan;27(1):50-2.

- [Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult!](#)  
*Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular...*5th September, 2008  
Department of Dermatology, Julius-Maximilians-University Wuerzburg,- Vasc Health Risk Manag. 2008;4(1):263-6.
- [Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.](#)  
*OBJECTIVE: To explore the impact of highly active antiretroviral therapy...*4th September, 2008  
Department of Epidemiology, Johns Hopkins University Bloomberg School of- J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90. ([DOI Direct Link](#))
- [Kaposi sarcoma: a continuing conundrum.](#)  
*Kaposi sarcoma (KS) remains a challenge. Its classic or Mediterranean form...*30th August, 2008  
Department of Dermatology, New Jersey Medical School, Newark, New Jersey- J Am Acad Dermatol. 2008 Aug;59(2):179-206; quiz 207-8. ([DOI Direct Link](#))
- [Editorial commentary: treatment of Kaposi sarcoma in the highly active antiretroviral therapy era.](#)  
*Kaposi sarcoma (KS) is a multifocal, vascular lesion of low-grade...*12th August, 2008  
- Clin Infect Dis. 2008 Aug 1;47(3):418-20. ([DOI Direct Link](#))
- [Kaposi sarcoma of the lung.](#)  
*Kaposi sarcoma (KS) is a multifocal, vascular lesion of low-grade...*30th July, 2008  
Department of Internal Medicine, University of British Columbia,- CMAJ. 2008 Jul 1;179(1):107. ([DOI Direct Link](#))
- [Kaposi sarcoma in unusual locations.](#)  
*Kaposi sarcoma (KS) is a multifocal, vascular lesion of low-grade...*23rd July, 2008  
Department of Pathology, Baystate Medical Center, Tufts University School- BMC Cancer. 2008 Jul 7;8:190. ([DOI Direct Link](#))

## BioNews Results for Sarcoma Kaposi

- [Lack of HAART and Low CD4 Cell Count Are Linked to Non-AIDS-related as well as Opportunistic Conditions](#)  
*HIV and Hepatitis.com: Oct 4 2008 12:24AM Matching: sarcoma kaposi*
- [Cancers in HIV: immunity/ART](#)  
*National AIDS Treatment Advocacy Project: Sep 27 2008 5:17PM Matching: sarcoma kaposi*
- [HIV services: caring for older patients](#)  
*Health Service Journal: Sep 22 2008 12:51AM Matching: sarcoma kaposi*
- [Switching from Protease Inhibitors to NNRTIs Is a Potential Risk Factor for Kaposi Sarcoma Relapse](#)  
*HIV and Hepatitis.com: Sep 19 2008 7:50PM Matching: sarcoma kaposi*
- [HIV progression slower in women than men in HAART era](#)  
*Clinical Lab Products: Sep 16 2008 5:34PM Matching: sarcoma kaposi*
- [Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sar](#)  
*Transplantation: Sep 13 2008 8:43AM Matching: sarcoma kaposi*
- [A reassessment of indications and diagnostic algorithms Bronchoscopy in HIV disease: An update in the era of H](#)  
*Consultant Live: Sep 9 2008 7:37AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*TickerTech.com: Sep 9 2008 12:08AM Matching: sarcoma kaposi*

- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*Montana's News Station: Sep 8 2008 2:59PM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*The Business Journal Phoenix: Sep 8 2008 11:49AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*Business Journal of Milwaukee: Sep 8 2008 11:46AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*Nashville Business Journal: Sep 8 2008 11:39AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*Cincinnati Business Journal: Sep 8 2008 11:34AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*San Francisco Business Times: Sep 8 2008 11:31AM Matching: sarcoma kaposi*
- [Ortho Biotech Files sNDA for DOXIL\(R\) for the Treatment of Advanced Breast Cancer](#)  
*Atlanta Business Chronicle: Sep 8 2008 11:27AM Matching: sarcoma kaposi*

### Sarcoma Kaposi Patents:



- 6020372- [Use of isoxazole and crotonamide derivatives for the treatment of carcinomatous disorders](#)
- 6432968- [Combination preparation, containing cyclosporin a or FK506 or rapamycin and a xanthine derivative](#)
- 6462075- [Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states](#)
- 6500431- [Inhibitors of angiogenesis and tumor growth](#)
- 6515001- [IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases](#)
- 6518269- [Cancer treatment](#)
- 6645731- [Methods and reagents for the rapid and efficient isolation of circulating cancer cells](#)
- 6693134- [Bicyclic aromatic chemokine receptor ligands](#)
- 6716863- [Heterocyclic compounds their production and use](#)
- 6727252- [Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds](#)
- 6759211- [Tumor growth inhibition- and apoptosis-associated genes and polypeptides and methods of use thereof](#)
- 6429204- [Method of inhibiting cancer growth](#)
- 6423734- [Method of preventing cancer](#)
- 6384049- [Cancer treatment](#)
- 6046328- [Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative](#)
- 6093728- [Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds](#)
- 6153603- [Method of treating angiogenesis in tumor tissue](#)
- 6172211- [Nucleic acid encoding tag7 polypeptide](#)
- 6180631- [Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds](#)
- 6204267- [Methods of modulating serine/threonine protein kinase function with quinazoline-based](#)

[compounds](#)

- 6290929- [Cancer treatment](#)
- 6309669- [Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix](#)
- 6323183- [Composition for and method of treatment using triterpenoids](#)
- 6365362- [Methods and reagents for the rapid and efficient isolation of circulating cancer cells](#)
- 6844010- [Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix](#)
- 6855723- [Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds](#)
- 7276506- [Immunosuppressive effects of pteridine derivatives](#)
- 7319145- [Methylenetetrahydrofolate reductase inhibitors and use thereof](#)
- 7332288- [Methods and reagents for the rapid and efficient isolation of circulating cancer cells](#)
- 7341730- [Inhibitors of angiogenesis and tumor growth](#)
- 7348003- [Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors](#)
- 7358278- [Cellular phosphorylation potential enhancing compositions preparation and use thereof](#)
- 7359748- [Apparatus for total immersion photography](#)
- 7361341- [Methods of treating cancer using antibodies that immunospecifically bind to trail receptors](#)
- 7402312- [Antibodies to vascular endothelial growth factor 2 \(VEGF-2\)](#)
- 7402592- [Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders](#)
- 7253176- [Immunosuppressive effects of 8-substituted xanthine derivatives](#)
- 7214686- [Pharmaceutical compositions and methods for effecting dopamine release](#)
- 7078385- [Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit I](#)
- 6861419- [Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 6902743- [Therapeutic treatment and prevention of infections with a bioactive material\(s\) encapsulated within a biodegradable-bio-compatible polymeric matrix](#)
- 6906091- [Method of cancer treatment](#)
- 6906105- [Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states](#)
- 6911446- [Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds](#)
- 6946465- [Immunosuppressive effects of pteridine derivatives](#)
- 6953855- [3-substituted-2\(arylalkyl\)-1-azabicycloalkanes and methods of use thereof](#)
- 6984653- [Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof](#)
- 7053050- [Preventives/remedies for proliferative organ diseases chronic arthritic diseases, hypertrophic scar or keloid](#)
- 7071222- [Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-\(4-trifluoromethyl\)-anilide and N-\(4-trifluoromethylphenyl\)2-cyano-3-hydroxycrotonic acid amide](#)
- 7425561- [3-substituted-2\(arylalkyl\)-1-azabicycloalkanes and methods of use thereof](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

